Germany's blue-chip DAX index ended Tuesday's session 0.10% in the green amid media reports suggesting Iran might restore access through the Strait of Hormuz in exchange for US military de-escalation.
Reuters reported, citing a senior Iranian official, that Tehran offered to reopen the strait within seven days if the US lifts its port blockade and eases military pressure, despite earlier warnings of retaliation "without limitations and considerations" against suspected upcoming US strikes. While US President Donald Trump signaled to Fox News that he was "probably" open to meeting his Iranian counterpart Masoud Pezeshkian at the UN General Assembly, the Iranian official cited by Reuters ruled out a leader-level meeting while insisting their New York delegation has full authority to revive diplomacy.
Closer to home, flash data from the European Commission showed that euro area consumer confidence fell to -16.5 points in September from -15.5 points in August. Analysts expected -16 points for the month.
On the corporate side, Siemens AG (SIE.F) edged up 0.37% after announcing that its transport technology unit, Siemens Mobility, secured a turnkey contract worth up to 1 billion euros from Vingroup's VinSpeed High-Speed Rail Investment and Development Joint Stock Co. to supply 10 Velaro Novo trains, communications, and electrification for two new high-speed rail lines in Vietnam. Under the deal, the German technology group's unit will serve as the technology partner, while VinSpeed will oversee track construction and civil works.
Meanwhile, RBC Capital Markets says investors are underestimating the financial upside of Siemens Healthineers' (SHL.F) new Varian radiotherapy linear accelerator platform expected to launch at the upcoming ASTRO conference starting Saturday. The research firm forecasts the launch will accelerate revenue growth and expand Varian's market-leading share of over 60% within the 6 billion-euro-plus radiotherapy sector.
"We expect the new platform to deepen an integrated ecosystem no competitor can replicate, driving both incremental equipment sales and higher-margin, recurring software/service revenue," RBC said. The German medical technology company lost 1.29% at the end of the trading day.